Antacids associated with reduced erlotinib efficacy By Laura Cowen.

As reported in Clinical Lung Cancer, sufferers in the AS group got considerably shorter median progression-free survival and overall survival weighed against those in the non-AS group, at 1.4 versus 2.3 months and 12.9 versus 16.8 months, respectively. After accounting for gender, NSCLC subtype and performance status, patients receiving AS experienced a substantial 1.83-fold increased risk of disease progression and a 1.37-fold increased risk of death compared with those who didn’t receive AS. The researchers also found that AS therapy was connected with a significantly worse objective response rate , and also lower prices of erlotinib treatment-limiting toxicity and TKI-related rash .The analysis was conduced by Victor Valderrabano, MD, and Beat Hintermann, MD, of Orthopaedic Section of the University of Basel Switzerland. The purpose of their research was to quantify the type of ligament injury that may become post-traumatic ankle arthritis. Osteoarthritis is the degeneration of a joint. Ankle ligament lesions, or sprains, are the most common injuries in sports and outdoor recreation. They account for about 25 percent of the accidents that occur in running and jumping sports activities. Related StoriesEmber Therapeutics reports initial results from BMP-7 Stage II trial in individuals with moderate osteoarthritis of the kneeLithium chloride could offer effective treatment against osteoarthritisResearchers develop novel technology for persistent arthritisSuch a disease causes inflammation, cartilage damage, formation of cysts, decrease in flexibility, and muscle mass imbalances in the effected joint.